| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 500mg | |||
| Other Sizes |
| ln Vivo |
Senecionine N-oxide was isolated from the alkaloidal mixture of Senecio triangularis and, together with senecionine, was concluded to be principally responsible for the tumor inhibitory activity of the alcoholic extract against the Walker 256 carcinosarcoma (intramuscular) in rats. However, the publication does not provide the specific T/C (test/control) values or tumor weight reduction data for the pure Senecionine N-oxide alone; the activity is attributed based on fractionation results where fractions lacking the alkaloids (B and C) were inactive, while the alkaloidal fractions (e.g., D and F) showed activity. For example, fraction D at 25 mg/kg gave a T/C of 16% (tumor weight test/control = 1.3/7.8 g) and at 20 mg/kg gave T/C 21% (1.7/7.8 g); fraction F at 50 mg/kg gave T/C 25% (1.8/7.0 g) and at 40 mg/kg gave T/C 21% (1.9/9.0 g). These fractions contained Senecionine N-oxide and senecionine [2].
|
|---|---|
| Animal Protocol |
The in vivo testing of fractions containing Senecionine N-oxide was performed using the Walker 256 carcinosarcoma tumor model implanted intramuscularly in rats. The publication does not provide detailed procedures for animal handling, tumor inoculation, dosing formulation, route of administration, or frequency of dosing for the pure compound. The assay evaluation followed the statistical sequential testing criteria of the Cancer Chemotherapy National Service Center (CCNSC), where a material is considered active if it causes reduction of tumor weight to ≤42% of control (T/C ≤ 42%) [2].
|
| ADME/Pharmacokinetics |
- In root cultures of Senecio vulgaris, Senecionine N-oxide newly synthesized from [¹⁴C]putrescine showed high metabolic stability. After a 24 h labeling period followed by 10 days of growth in non-radioactive medium, the amount of radioactive Senecionine N-oxide remained unchanged or even increased (e.g., from 45% to 57% of total ¹⁴C-activity in MeOH extracts), indicating that it behaves as a metabolic end product with no significant turnover or degradation [1].
- Senecionine N-oxide is susceptible to spontaneous chemical reduction to the corresponding tertiary alkaloid (senecionine) under various conditions. Prolonged refluxing with methanol (Soxhlet extraction for 48 h) caused ~50% reduction in the presence of plant material; acid macerate (0.25 M H₂SO₄, 24 h at 50°C) caused ~30% reduction; incubation with 1 mg/mL cysteine for 24 h at 25°C caused 15% reduction, and at 55°C caused 43% reduction. Reduction also occurs in the presence of plant-derived reducing agents (e.g., thiols) [1]. |
| References |
|
| Additional Infomation |
Seneciolide N-oxide is a tertiary amine oxide whose function is related to that of seneciolide. It has been reported that seneciolide N-oxide exists in Senecio scandens, Senecio scutellaria, and other organisms with relevant data.
- Senecionine N-oxide is the naturally occurring form of pyrrolizidine alkaloids in Senecio vulgaris root cultures and intact plants, accounting for >90% of total alkaloids under standard extraction procedures that prevent spontaneous reduction. The tertiary alkaloid (senecionine) is present only in trace amounts, mainly in old tissues, and is easily formed artificially during extraction [1]. - The N-oxide form is highly polar, salt-like, water-soluble, and insoluble in most organic solvents, which prevents non-specific permeation across biological membranes. This property is suggested to facilitate safe vacuolar storage and translocation compared to the tertiary alkaloid [1]. - Senecio species, including Senecio vulgaris which contains Senecionine N-oxide, have been used historically in folk medicine since the 4th century A.D. for “tumors of the feet and sinews” and since the 10th century for cancer. Other genera containing pyrrolizidine alkaloids (e.g., Petasites, Cynoglossum, Echium, Heliotropium, Tournefortia, Cytisus) have also been described as folk remedies for cancer [2]. |
| Molecular Formula |
C18H25NO6
|
|---|---|
| Molecular Weight |
351.3942
|
| Exact Mass |
351.168
|
| CAS # |
13268-67-2
|
| Related CAS # |
Senecionine N-oxide-d3
|
| PubChem CID |
5380876
|
| Appearance |
White to off-white solid
|
| LogP |
1.164
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
25
|
| Complexity |
656
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
O1C(/C(=C(/[H])\C([H])([H])[H])/C([H])([H])[C@@]([H])(C([H])([H])[H])[C@](C([H])([H])[H])(C(=O)OC([H])([H])C2=C([H])C([H])([H])[N+]3(C([H])([H])C([H])([H])[C@]1([H])[C@]32[H])[O-])O[H])=O
|
| InChi Key |
PLGBHVNNYDZWGZ-GPUZEBNTSA-N
|
| InChi Code |
InChI=1S/C18H25NO6/c1-4-12-9-11(2)18(3,22)17(21)24-10-13-5-7-19(23)8-6-14(15(13)19)25-16(12)20/h4-5,11,14-15,22H,6-10H2,1-3H3/b12-4-/t11-,14-,15-,18-,19?/m1/s1
|
| Chemical Name |
(1R,4Z,6R,7R,17R)-4-ethylidene-7-hydroxy-6,7-dimethyl-14-oxido-2,9-dioxa-14-azoniatricyclo[9.5.1.014,17]heptadec-11-ene-3,8-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~142.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8458 mL | 14.2292 mL | 28.4584 mL | |
| 5 mM | 0.5692 mL | 2.8458 mL | 5.6917 mL | |
| 10 mM | 0.2846 mL | 1.4229 mL | 2.8458 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
